Sumin began her career in McKinsey & Co’s healthcare practice. She served pharma and biotech clients, focused on Merger & Acquisitions and R&D strategy / operations. Post-McKinsey, she joined Novartis to run late-stage clinical trials and shepherded assets through to obtain FDA License approvals. She later became Vice President of Haemonetics, a $4B medical device public company, supporting the CEO as Chief of Staff on the company’s turnaround.
Most recently, she led the due diligence for impact investors on a £80M acquisition of a distressed diagnostic company during her time at Bill and Melinda Gates Foundation. She was subsequently appointed by the NewCo’s Board Chair to be its interim CEO to lead its turnaround.
Umbrex independent consultants are available where you need them – in all major markets and every global region.